Loading
A phase 3 trial in lung cancer, run by Tata Memorial Hospital, now recruiting.
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT is a phase 3, randomised interventional study registered as NCT05236946 by Tata Memorial Hospital, with a registry enrolment figure of 190 participants, started 2020-11-10 and due to reach its primary completion in 2025-12. Interventions recorded: Stereotactic radiosurgery/whole brain radiotherapy; Tyrosine kinase inhibitor. Conditions listed: Asymptomatic Brain Metastases; Driver Mutation Positive Non-small Cell Lung Cancer. Primary outcome: Intracranial progression free survival at 24 months. Lung eligibility wording from the registry: "Patients with pathologically proven diagnosis of NSCLC". Sites: India. No results are recorded here; the registry entry is the source.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.